LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

Home・Akcijų sąrašas・Cogent Biosciences Inc

Cogent Biosciences Inc

Uždarymo kaina

35.68 5.31

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

Max

37.06

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-22M -102M
Pelnas, tenkantis vienai akcijai	-0.5
Darbuotojai	258
EBITDA	-30M -109M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+54.56% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	399M 6B
Ankstesnė atidarymo kaina	30.37
Ankstesnė uždarymo kaina	35.68

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

4.88 / 5.87 Palaikymas ir pasipriešinimas

Cogent Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-16 21:37; UTC

Įsigijimai, susijungimai, perėmimai

Lensar and Alcon Agree to Terminate Merger

2026-03-16 19:06; UTC

Svarbiausios naujienos

Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS

2026-03-16 17:44; UTC

Įsigijimai, susijungimai, perėmimai

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

2026-03-16 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-16 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise After Oil Prices Decline -- Market Talk

2026-03-16 23:37; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Technical Recovery -- Market Talk

2026-03-16 23:05; UTC

Rinkos pokalbiai

Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk

2026-03-16 21:56; UTC

Rinkos pokalbiai

DUG Technology's Stock Fall Creates Opportunity -- Market Talk

2026-03-16 21:41; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Equities Roundup: Market Talk

2026-03-16 21:41; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk

2026-03-16 20:59; UTC

Įsigijimai, susijungimai, perėmimai

Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition

2026-03-16 20:59; UTC

Įsigijimai, susijungimai, perėmimai

Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further

2026-03-16 20:59; UTC

Įsigijimai, susijungimai, perėmimai

Alcon Entered Agreement With LENSAR to Terminate Merger Agreement

2026-03-16 20:57; UTC

Įsigijimai, susijungimai, perėmimai

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

2026-03-16 20:51; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ

2026-03-16 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-03-16 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Energy & Utilities Roundup: Market Talk

2026-03-16 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-03-16 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-16 19:53; UTC

Svarbiausios naujienos

U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ

2026-03-16 19:43; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-16 19:43; UTC

Rinkos pokalbiai

Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk

2026-03-16 19:37; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Natural Gas Follows Oil Prices Lower -- Market Talk

2026-03-16 19:20; UTC

Svarbiausios naujienos

Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ

2026-03-16 19:17; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk

2026-03-16 19:00; UTC

Rinkos pokalbiai

Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk

2026-03-16 18:23; UTC

Rinkos pokalbiai

LME Restarts Trading After Outage -- Market Talk

2026-03-16 17:36; UTC

Svarbiausios naujienos

Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com

2026-03-16 17:19; UTC

Rinkos pokalbiai

Grains Sink as Investors Steer Toward Equities -- Market Talk

2026-03-16 17:14; UTC

Svarbiausios naujienos

Trump Ends News Conference

Akcijų palyginimas

Kainos pokytis

Cogent Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

54.56% į viršų

12 mėnesių prognozė

Vidutinis 52.55 USD 54.56%

Aukščiausias 64 USD

Žemiausias 35 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Cogent Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

Pirkti

Laikyti

Parduoti

Remiantis 12 analitikų, pateikusių Cogent Biosciences Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

4.88 / 5.87Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.